多沙普仑杂质 | 42595-88-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 多沙普仑杂质
• 英文名称: 2-Ketodoxapram
• 英文别名: 4-[2-(1-ethyl-5-oxo-4,4-diphenylpyrrolidin-3-yl)ethyl]morpholin-3-one
• CAS: 42595-88-0
• 化学式: C₂₄H₂₈N₂O₃
• 分子量: 392.5
• InChiKey: LLCHHQQQMSDZLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF
  申请人：Hsu, John

  公开号：EP3801545A1

  公开（公告）日：2021-04-14
• TASK-1 INHIBITORS FOR TREATMENT OF ATRIAL ARRHYTHMIAS
  申请人：Universität Heidelberg

  公开号：EP3836918A1

  公开（公告）日：2021-06-23
• [EN] COMPOSITIONS AND METHODS FOR TREATING BREATHING CONTROL DISORDERS OR DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITEMENT DES TROUBLES OU MALADIES DE LA RÉGULATION DE LA RESPIRATION
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2012166909A1

  公开（公告）日：2012-12-06

  The present invention includes a method of treating a breathing control disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising (+)-ketodoxapram or a solvate thereof and a pharmaceutically acceptable carrier, wherein the composition is essentially free of (— )-ketodoxapram or a solvate thereof.
• [EN] TASK-1 INHIBITORS FOR TREATMENT OF ATRIAL ARRHYTHMIAS<br/>[FR] INHIBITEURS TASK-1 POUR LE TRAITEMENT D'ARYTHMIES AURICULAIRES
  申请人：UNIV HEIDELBERG

  公开号：WO2020035541A1

  公开（公告）日：2020-02-20

  The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R1 is ethyl, -H, or methyl and R2 is a side chain having a structure as shown in formula (II) wherein X1 is C=O, CH2, C=S, C-OH, C-NH2, or C-NO2, X2 to X4 are independently selected from CH2, C=O, C=S, C-OH, and C-NH2, or R2 is -NH2, for use in treating and/or preventing of atrial arrhythmia in a subject. The present invention further relates to pharmaceutical compositions and kit related to said compound.